Clinical Trial Update: RESPONSE: Response to Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Control to or an Intolerance to Ursodeoxycholic Acid (UDCA) [Phase 3]

View source ↗

Summary

Phase 3 trial of seladelpar in primary biliary cholangitis has completed, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Biliary Cholangitis

Drugs mentioned

• Seladelpar (seladelpar)

Snippet

Sponsor: Gilead Sciences | Conditions: Primary Biliary Cholangitis | Phase 3 | Status: COMPLETED | Results posted: 2024-07-25